The risk of transfusion and transplant-related Hepatitis B (HBV) and Hepatitis C (HCV) transmission has been steadily reduced through adoption of routine screening for Hepatitis B surface antigen (HBsAg), anti-Hepatitis B core antigen (anti-HBc), and anti-Hepatitis C. Despite their utility, these antibody-based assays are prone to false positive results, and due to inherent test sensitivity and/or dependence on host response, are also limited by a substantial window period between infection and detection. The more recently available nucleic acid testing (NAT), offers improved sensitivity and specificity over antibody-based assays, significantly decreasing the acute infection window period and improving detection of infections well into late chronic phases. Concurrent NAT testing is suspected to be useful for differentiating serological false
positive results from true infected potential donors. Blood transfusion literature has shown that 2-16% of donors that tested positive for HBsAg were in fact HBV DNA negative after NAT. 1 The aim of this study was to determine the true incidence of HBV and HCV in potential gamete donors, and evaluate if a re-entry protocol for suspected false positive results using concurrent NAT testing should be considered.
Design:
Retrospective, cohort study
Materials and Methods:
The study included 1396 gamete donors presenting at various donation sites between 2016 and 2018 and being screened for HBV and HCV. HBsAg, anti-HBc, HCV antibody, and triplex (HIV-1, HCV, HBV) NAT results were analyzed. Serologic and virologic results were compared. Charts of donors testing positive were reviewed manually for accuracy.
Results:
Of the 1041 sperm donors and 355 egg donors included in this study, 6 (0.58%) sperm donors and 4 egg donors (1.12%) were found to be positive for either HBsAg or anti-HBc (Table 1) .
Two of the sperm donors were found to have an active infection (positive HbsAg and Anti-HBc, (Table 2) , suggesting a 100% false positive rate.
Conclusions:
This study demonstrated the true positive rate for HBV and HCV was low in the gamete donor population, whereas the false positive rate was substantial (at least 40% for HBV and 100% for HCV). Universal concurrent testing with NAT is currently recommended by FDA for blood and tissue donors. Experts suggest that a combination of Triplex NAT and anti-HBc testing is ideal, as it allows earlier detection of HBV infection, and captures individuals with chronic infections and low DNA levels. 2 Conversely, HBsAg testing has not been shown to provide additional information over NAT testing alone, and may ultimately become obsolete in donor screening programs. Given the currently lack of a re-entry protocol for presumed false positive testing results, current requirements for permanent deferral for any positive screening test result leads to unnecessary donor loss. While patient safety must always be prioritized, gamete donors are a scarce resource, and deferral based on spurious values creates issues for donor supply, particularly in cases where sibling pregnancies are desired. Particularly given the numerous opportunities for retesting a sperm donor within the 6 month quarantine period, a rigorous reentry process for gamete donors, similar to that allowed for blood donors, should be considered.
Accumulating data strongly suggests that HBsAg testing may add little, if any, HBV risk reduction value when HBV NAT and anti-HBc screening also apply. 
